EndoCeutics Inc.   Report issue

Contributed to NME For profit Phase 3
Founded: Quebec Quebec Canada (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2007
NCT01846442
First Marketed Drug
2016
prasterone (intrarosa)
First NDA Approval
2016
prasterone (intrarosa)
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

EndoCeutics Inc. | Endoceutics, Inc., Quebec, Canada

Active Ingredients

Marketed Drugs (1)

prasterone (intrarosa) (2016 NDA)

Drugs in Phase 3 Trials (4)

dehydroepiandrosterone (4 trials)

icosapent ethyl (vascepa) (1 trial)

prasterone (intrarosa) (5 trials)

ritetronium (1 trial)

Indications

Approved Indications


 

Arthritis, Rheumatoid

Dysmenorrhea

Dyspareunia

Osteoarthritis

Pain

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Breast Neoplasms (Phase 3)

Disease (Phase 3)

Dyspareunia (Phase 3)

Flushing (Phase 3)

Hot Flashes (Phase 3)

Hypokinesia (Phase 3)

Sexual Dysfunctions, Psychological (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 4